What is Emergent Biosolutions's total revenue?

Emergent Biosolutions (EBS) reported total revenue of $156.1M in Q1 2026.

How has Emergent Biosolutions's total revenue changed year-over-year?

Emergent Biosolutions's total revenue decreased by 29.7% year-over-year, from $222.2M to $156.1M.

What is the long-term trend for Emergent Biosolutions's total revenue?

Over 4 years (2021 to 2025), Emergent Biosolutions's total revenue has grown at a -19.6% compound annual growth rate (CAGR), from $1.77B to $742.9M.

What does total revenue mean?

The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.

Emergent Biosolutions EBS Total Revenue

Total Revenue at other companies

Thermo Fisher ScientificTMO

$11.01B+6.2%

Regeneron PharmaceuticalsREGN

$3.61B+19.0%

AMP

Amphastar PharmaceuticalsAMPH

$171.17M+0.4%

Amneal Pharmaceuticals, Inc.AMRX

$722.52M+3.9%

Collegium Pharmaceutical, Inc.COLL

$193.52M+8.9%

Opko HealthOPK

$124.2M-17.2%

Segments

By product

See full

MCM Product sales$101.8M-35.0%

Commercial Product sales$42.9M-5.3%

All other revenue$11.4M-43.8%

By segment

See full

MCM Products$101.8M-35.0%

Commercial Products$42.9M-5.3%

By geography

See full

Canada$224.2M+50.9%

Other financials

Income statement

See full

Gross profit$84.1M-37.1%

Operating income$10.5M-79.0%

Net income$6.8M-90.0%

EPS (diluted)$0.07-94.1%

Balance sheet

See full

Cash & equivalents$161.5M+5.7%

Total debt$584.6M-13.1%

Total equity$523.1M-5.4%

Total assets$1.3B-7.4%

Cash flow

See full

Operating cash flow-$33.8M-202%

CapEx$2.4M-33.3%

Free cash flow-$36.2M-145%

Valuation

See full

Market cap$411.74M+22.0%

Enterprise value$834.84M-2.6%

P/E3.6×—

P/S0.6×+0.3×

Profitability

See full

Gross margin54.2%+19.0pp

Operating margin15%+10.3pp

Net margin9.6%+5.8pp

FCF margin20.8%—

Returns & leverage

See full

Return on equity13.9%+8.1pp

Debt / equity1.1×-0.1×

Current ratio4.3×-2.0×

Where this comes from

Reported directly by Emergent Biosolutions in its filing.

Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.

The official record: Emergent Biosolutions’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Emergent Biosolutions's total revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Emergent Biosolutions's total revenue?: Emergent Biosolutions (EBS) reported total revenue of $156.1M in Q1 2026.
How has Emergent Biosolutions's total revenue changed year-over-year?: Emergent Biosolutions's total revenue decreased by 29.7% year-over-year, from $222.2M to $156.1M.
What is the long-term trend for Emergent Biosolutions's total revenue?: Over 4 years (2021 to 2025), Emergent Biosolutions's total revenue has grown at a -19.6% compound annual growth rate (CAGR), from $1.77B to $742.9M.
What does total revenue mean?: The aggregate of all revenue from the company's operations — the top line from which all profitability metrics are derived.